This company is no longer in business. Investors can get details about any potential exits or failures here.

Facible BioDiagnostics

Facible BioDiagnostics

Growth Stage

Leading the Biodiagnostic Testing Revolution

Leading the Biodiagnostic Testing Revolution


Funding data not publicly available

Rialto Markets

Start Date


Close Date

Not Provided

Min. Goal
Max. Goal
Min. Investment


Security Type

Equity - Common


Series A

SEC Filing Type

RegA+    Open SEC Filing

Price Per Share


Pre-Money Valuation


Year Founded



Healthcare & Pharmaceuticals

Tech Sector


Distribution Model




Capital Intensity



Meridian, Idaho

Business Type

High Growth

Facible BioDiagnostics is raising funds on Rialto Markets through Reg A+ crowdfunding. The company has developed a new technology for diagnostic testing to deliver fast and accurate results in the detection of viruses, bacteria, and other contaminants. The technology is called Quantum-Logic Anazyme Analyte Detection (Q-LAAD) and is specifically used for COVID testing. Facible BioDiagnostics has signed an LOI with a distributor for 18 million units and estimates its gross profit margin to be 93.57%. Steven Burden, Clementine Gibard Bohachek, and Hunter Covert founded Facible BioDiagnostics in 2022. The current crowdfunding campaign has a maximum target of $40,000,000. The campaign proceeds will be used for research and development, clinical testing, and working capital.

Balance Sheet

Cash and Cash Equivalents


Property, Plant and Equipment (PP&E)


Total Assets


Accounts Payable & Accrued Liabilities


Long Term Debt


Total Liabilities


Total Stockholders' Equity


Total Liabilities and Equity


Statement of Comprehensive Income Information

Costs & Expenses Applicable to Rev


Depreciation and Amortization


Net Income


Earnings Per Share - Basic


Earnings Per Share - Diluted


Auditor: Assurance Dimensions
Financials as of: 07/27/2022
Create a free account today to gain access to KingsCrowd analytics.

Funding data not publicly available

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Facible BioDiagnostics on Rialto Markets 2022
Platform: Rialto Markets
Security Type: Equity - Common
Valuation: $702,724,398
Price per Share: $5.80

Follow company

Follow Facible BioDiagnostics on Rialto Markets 2022

Buy Facible BioDiagnostics's Deal Report

Warning: according to the close date for this deal, Facible BioDiagnostics may no longer be accepting investments.

Facible BioDiagnostics Deal Report

Get KingsCrowd’s comprehensive report on Facible BioDiagnostics including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Facible BioDiagnostics is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Facible BioDiagnostics deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge